Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496518 | 1.00 | P2RY12 (0.52) | P2RY12ADORA3BMPR1BADORA1ADORA2A | |
| SCHEMBL20149803 | 0.93 | ALDH1A1 (0.54) | P2RY12ADORA3BMPR1BADORA1ADORA2A | |
| SCHEMBL15953489 | 0.93 | ADORA1 (0.56) | P2RY12ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL25496497 | 0.93 | ADORA1 (0.56) | P2RY12ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL15953492 | 0.93 | ADORA1 (0.56) | P2RY12ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20149805 | 0.91 | PRMT6 (0.47) | P2RY12ADORA3BMPR1BADORA1ADORA2A | |
| SCHEMBL25496726 | 0.91 | PRMT6 (0.47) | P2RY12ADORA3BMPR1BADORA1ADORA2A | |
| SCHEMBL16261025 | 0.90 | PRMT6 (0.51) | P2RY12ADORA3BMPR1BADORA1ADORA2A | |
| SCHEMBL20149808 | 0.89 | PRMT6 (0.47) | P2RY12ADORA3BMPR1BADORA1ADORA2A | |
| SCHEMBL14364928 | 0.88 | PRMT6 (0.58) | P2RY12BMPR1BP2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | P2RY12 3905/4885ADORA3 985/4885BMPR1B 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.